Literature DB >> 20068403

Keystone Symposium on Antibodies as Drugs: March 27-April 1, 2009, Whistler, BC CA.

Thierry Wurch1, Christel Larbouret, Bruno Robert.   

Abstract

The symposium on Antibodies as Drugs, organized by Keystone Symposia and chaired by J. Marks, (University of California Los Angeles, USA), E.S. Ward (University of Texas Southwestern Medical Center, USA) and L. Weiner (Georgetown University Medical Center, USA), was held in Whistler, British Columbia. This Canadian Rockies village, which will host the 2010 Olympic Games, served as an enchanting backdrop to the meeting. The more than 350 speakers and attendees included scientists from major pharmaceutical firms, e.g., Abbott, MedImmune/Astra Zeneca, Bristol-Myers Squibb, Merck & Co., Pfizer, Sanofi-Aventis, Schering, GlaxoSmithKline, Eli Lilly, Hoffmann LaRoche, Novartis, Wyeth, and biotechnology companies, e.g., Ablynx, Medarex, Morphosys, GenMab, Amgen, Genentech, ImmunoGen, Agensys, Domantis, Biogen Idec, Centocor, LFB, Micromet, PDL Biopharma, Borean Pharma, Dyax Corp., Symphogen and Syntonix. Academic research groups at Imperial College London, University of Oxford, ETH Zürich, Scripps, Institute Cochin, Karolinska Institute, Utrecht University, Harvard Medical School, Massachusetts Institute of Technology, Baylor College, Paul Ehrlich Institute, University of California San Francisco, University of California San Diego, University of Nantes, University of Tours and Ludwig Institute were also represented, as were regulatory authorities, including the US Food and Drug Administration, National Institutes of Health and the Public Health Agency of Canada). The meeting was very interactive and included thoughtful exchanges during the different sessions and networking events.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20068403      PMCID: PMC2726610          DOI: 10.4161/mabs.1.4.9123

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  15 in total

Review 1.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

2.  A stapled BID BH3 helix directly binds and activates BAX.

Authors:  Loren D Walensky; Kenneth Pitter; Joel Morash; Kyoung Joon Oh; Scott Barbuto; Jill Fisher; Eric Smith; Gregory L Verdine; Stanley J Korsmeyer
Journal:  Mol Cell       Date:  2006-10-20       Impact factor: 17.970

3.  Mining a yeast library for brain endothelial cell-binding antibodies.

Authors:  Xin Xiang Wang; Yong Ku Cho; Eric V Shusta
Journal:  Nat Methods       Date:  2007-01-07       Impact factor: 28.547

4.  Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide.

Authors:  Federico Bernal; Andrew F Tyler; Stanley J Korsmeyer; Loren D Walensky; Gregory L Verdine
Journal:  J Am Chem Soc       Date:  2007-02-07       Impact factor: 15.419

5.  Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice.

Authors:  Héctor Pérez Montoyo; Carlos Vaccaro; Martin Hafner; Raimund J Ober; Werner Mueller; E Sally Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

6.  Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.

Authors:  Seung Y Chu; Igor Vostiar; Sher Karki; Gregory L Moore; Greg A Lazar; Erik Pong; Patrick F Joyce; David E Szymkowski; John R Desjarlais
Journal:  Mol Immunol       Date:  2008-08-08       Impact factor: 4.407

7.  A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

Authors:  Si Tuen Lee-Hoeflich; Lisa Crocker; Evelyn Yao; Thinh Pham; Xander Munroe; Klaus P Hoeflich; Mark X Sliwkowski; Howard M Stern
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

8.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

Authors:  Chengbin Wu; Hua Ying; Christine Grinnell; Shaughn Bryant; Renee Miller; Anca Clabbers; Sahana Bose; Donna McCarthy; Rong-Rong Zhu; Ling Santora; Rachel Davis-Taber; Yune Kunes; Emma Fung; Annette Schwartz; Paul Sakorafas; Jijie Gu; Edit Tarcsa; Anwar Murtaza; Tariq Ghayur
Journal:  Nat Biotechnol       Date:  2007-10-14       Impact factor: 54.908

9.  Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

Authors:  Sonia Lain; Jonathan J Hollick; Johanna Campbell; Oliver D Staples; Maureen Higgins; Mustapha Aoubala; Anna McCarthy; Virginia Appleyard; Karen E Murray; Lee Baker; Alastair Thompson; Joanne Mathers; Stephen J Holland; Michael J R Stark; Georgia Pass; Julie Woods; David P Lane; Nicholas J Westwood
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

Review 10.  Updates on p53: modulation of p53 degradation as a therapeutic approach.

Authors:  A Dey; C S Verma; D P Lane
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.